ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Reproductive Issues in Rheumatic Disorders - Poster

Date: Tuesday, November 15, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM
Abstract Number: 2436
Birth Outcomes Significantly Worsen after the Development of Systemic Lupus Erythematosus in a Population-Based Registry
9:00AM-11:00AM
Abstract Number: 2437
Causes of Cesarean Section and Labor Induction in Systemic Lupus Erythematosus and Rheumatoid Arthritis Pregnancies
9:00AM-11:00AM
Abstract Number: 2454
Cohort of Pregnant Women with Ro/La Antibodies: Risk of Fetal Third Degree Atrioventricular Block and Use of Hydroxychloroquine
9:00AM-11:00AM
Abstract Number: 2448
Contraceptive Methods in Women with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2435
Counseling on Family Planning and Contraception, and Pregnancy Outcome in Women with Rheumatic Diseases: Analysis of 398 Patient-Reported Questionnaires from a Multicenter Italian Study
9:00AM-11:00AM
Abstract Number: 2445
Dermatomyositis and Pregnancy: Assessment of Disease Activity and Pregnancy Outcomes Complicated By Maternal Dermatomyositis
9:00AM-11:00AM
Abstract Number: 2450
Do Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis Have Reduced Fertility and Parity? a Systematic Review
9:00AM-11:00AM
Abstract Number: 2447
Does a History of Abnormal Pap Smear or Preceeding HPV Infection Affect Humoral Immune Response to Quadrivalent Human Papilloma Virus (qHPV) Vaccine in Women with Systemic Lupus Erythematosus (SLE)
9:00AM-11:00AM
Abstract Number: 2439
Effect of Pregnancy Counseling on the Outcome of Pregnancies in Women with Systemic Lupus Erythematosus: A Prospective Observational Study
9:00AM-11:00AM
Abstract Number: 2444
Effects of Disease Activity and Drug Exposure on Pregnancy Outcomes with Inflammatory Arthritis
9:00AM-11:00AM
Abstract Number: 2459
Epidemiologic Profile of Erectile Dysfunction in SLE: A Multi-Center Study in Latin American Patients
9:00AM-11:00AM
Abstract Number: 2458
Erectile Dysfunction in Men with Rheumatic Diseases: A Systematic Review
9:00AM-11:00AM
Abstract Number: 2451
Evaluation of Ovarian Reserve and Function in Adolescent Females with Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2440
First Results from the Prospective German Pregnancy Register
9:00AM-11:00AM
Abstract Number: 2438
Increased Risk of Postpartum Depression in SLE Pregnancies
9:00AM-11:00AM
Abstract Number: 2446
Infantile Hemangiomas in Infants Born to Women with Autoimmune Diseases
9:00AM-11:00AM
Abstract Number: 2449
Infertility in Women with Rheumatoid Arthritis
9:00AM-11:00AM
Abstract Number: 2443
Pregnancy Comorbidities and Outcomes in Psoriasis and Psoriatic Arthritis: A Prospective Cohort Study
9:00AM-11:00AM
Abstract Number: 2452
Reduced Ovarian Reserve in Young Juvenile Idiopathic Arthritis Patients
9:00AM-11:00AM
Abstract Number: 2441
Rheumatoid Arthritis Flares and Pregnancy Outcomes Among Women in a Longitudinal Registry
9:00AM-11:00AM
Abstract Number: 2456
Risk Factors for Adverse Pregnancy Outcome in Antiphospholipid Antibodies Carriers: Results from a Multicenter Italian Cohort over 20 Years of Experience
9:00AM-11:00AM
Abstract Number: 2457
Role of Hydroxychloroquine in Improving  Pregnancy Outcomes in Women with Antiphospholipid Antibodies without Other Underlying Connective Tissue Disease
9:00AM-11:00AM
Abstract Number: 2453
The Prevention, Screening, and Treatment of Congenital Heart Block from Neonatal Lupus: A Survey of Provider Practices
9:00AM-11:00AM
Abstract Number: 2455
Transcriptome Profile of Cells Isolated from a CHB Heart Support an Exuberant Inflammatory ⁄Pro-Fibrotic Cascade
9:00AM-11:00AM
Abstract Number: 2433
Trends  in Use of Hydroxychloroquine during Pregnancy in SLE Patients from 2001 to 2012
9:00AM-11:00AM
Abstract Number: 2442
Use of Nonsteroidal Anti-Inflammatory Drugs in Pregnant Women with Inflammatory Arthritis

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology